Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Consensus Target Price from Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been given an average rating of “Hold” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $7.75.

A number of equities research analysts have recently issued reports on BHC shares. Royal Bank of Canada boosted their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Finally, StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th.

Bausch Health Companies Stock Performance

Bausch Health Companies stock opened at $7.73 on Thursday. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The stock has a fifty day moving average of $7.86 and a 200 day moving average of $7.45. The stock has a market cap of $2.79 billion, a PE ratio of -16.09 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.02 by $0.10. The firm had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.03 EPS. As a group, sell-side analysts predict that Bausch Health Companies will post 3.73 EPS for the current fiscal year.

Institutional Trading of Bausch Health Companies

Several institutional investors have recently made changes to their positions in the business. Goldentree Asset Management LP boosted its stake in Bausch Health Companies by 31.0% in the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after purchasing an additional 6,958,717 shares during the period. Bank of Montreal Can lifted its holdings in shares of Bausch Health Companies by 234.0% in the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after buying an additional 2,685,675 shares in the last quarter. Maple Rock Capital Partners Inc. bought a new position in shares of Bausch Health Companies during the third quarter worth $16,850,000. SG Americas Securities LLC grew its stake in Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after acquiring an additional 1,263,706 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after acquiring an additional 1,252,834 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.